CN113893350A - 一种治疗癌症的组合物及其应用和药物 - Google Patents
一种治疗癌症的组合物及其应用和药物 Download PDFInfo
- Publication number
- CN113893350A CN113893350A CN202010641456.1A CN202010641456A CN113893350A CN 113893350 A CN113893350 A CN 113893350A CN 202010641456 A CN202010641456 A CN 202010641456A CN 113893350 A CN113893350 A CN 113893350A
- Authority
- CN
- China
- Prior art keywords
- cancer
- vegfr2
- sglt1
- inhibitor
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/005—Enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
- A61K38/1866—Vascular endothelial growth factor [VEGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
Abstract
Description
Claims (11)
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311041001.6A CN117018204A (zh) | 2020-07-06 | 2020-07-06 | 一种治疗癌症的组合物及其应用和药物 |
CN202010641456.1A CN113893350B (zh) | 2020-07-06 | 2020-07-06 | 一种治疗癌症的组合物及其应用和药物 |
PCT/CN2020/109967 WO2022007135A1 (zh) | 2020-07-06 | 2020-08-19 | 一种治疗癌症的组合物及其应用和药物 |
US17/292,835 US20220305072A1 (en) | 2020-07-06 | 2020-08-19 | Composition for treating cancer and use and medicament thereof |
JP2021525310A JP7382660B2 (ja) | 2020-07-06 | 2020-08-19 | がん治療用組成物及びその応用、並びに医薬品 |
EP20880381.7A EP3957329A1 (en) | 2020-07-06 | 2020-08-19 | Composition for treating cancer, application thereof, and drug |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010641456.1A CN113893350B (zh) | 2020-07-06 | 2020-07-06 | 一种治疗癌症的组合物及其应用和药物 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311041001.6A Division CN117018204A (zh) | 2020-07-06 | 2020-07-06 | 一种治疗癌症的组合物及其应用和药物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113893350A true CN113893350A (zh) | 2022-01-07 |
CN113893350B CN113893350B (zh) | 2023-09-15 |
Family
ID=78617117
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311041001.6A Pending CN117018204A (zh) | 2020-07-06 | 2020-07-06 | 一种治疗癌症的组合物及其应用和药物 |
CN202010641456.1A Active CN113893350B (zh) | 2020-07-06 | 2020-07-06 | 一种治疗癌症的组合物及其应用和药物 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311041001.6A Pending CN117018204A (zh) | 2020-07-06 | 2020-07-06 | 一种治疗癌症的组合物及其应用和药物 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20220305072A1 (zh) |
EP (1) | EP3957329A1 (zh) |
JP (1) | JP7382660B2 (zh) |
CN (2) | CN117018204A (zh) |
WO (1) | WO2022007135A1 (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117599188A (zh) * | 2020-07-06 | 2024-02-27 | 诺未科技(北京)有限公司 | 组合物及其在制备治疗癌症的药物中的应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104436194A (zh) * | 2013-09-18 | 2015-03-25 | 北京大学 | 具有协同增效作用的抗癌组合物 |
CN105358173A (zh) * | 2013-05-08 | 2016-02-24 | 休斯敦系统大学 | 靶向癌症治疗的egfr-sglt1相互作用 |
CN110430876A (zh) * | 2017-03-13 | 2019-11-08 | 基恩菲特公司 | 用于组合疗法的药物组合物 |
CN111150848A (zh) * | 2020-01-21 | 2020-05-15 | 中国药科大学 | Plagl2及其在肝癌中的应用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3060654B1 (en) * | 2013-10-21 | 2023-03-15 | Hemoshear, LLC | In vitro model for a tumor microenvironment |
CA3102279A1 (en) * | 2018-06-01 | 2019-12-05 | Cornell University | Combination therapy for pi3k-associated disease or disorder |
BR112021004839A2 (pt) * | 2018-09-26 | 2021-06-08 | Lexicon Pharmaceuticals, Inc. | formas cristalinas de n-(1-((2-(dimetilamino)etil)amino)-2-metil-1-oxopropan-2-il)-4-(4-(2-metil-5-((2s,3r,4r,5s,6r)-3,4,5-triidróxi-6-(metiltio)tetraidro-2h-piran-2-il)benzil)fenil)butanamida e métodos de sua síntese |
CN113893256A (zh) * | 2020-07-06 | 2022-01-07 | 诺未科技(北京)有限公司 | 化合物或其可药用盐、二聚体或三聚体在制备治疗癌症的药物中的应用 |
CN117599188A (zh) * | 2020-07-06 | 2024-02-27 | 诺未科技(北京)有限公司 | 组合物及其在制备治疗癌症的药物中的应用 |
-
2020
- 2020-07-06 CN CN202311041001.6A patent/CN117018204A/zh active Pending
- 2020-07-06 CN CN202010641456.1A patent/CN113893350B/zh active Active
- 2020-08-19 EP EP20880381.7A patent/EP3957329A1/en active Pending
- 2020-08-19 WO PCT/CN2020/109967 patent/WO2022007135A1/zh unknown
- 2020-08-19 US US17/292,835 patent/US20220305072A1/en active Pending
- 2020-08-19 JP JP2021525310A patent/JP7382660B2/ja active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105358173A (zh) * | 2013-05-08 | 2016-02-24 | 休斯敦系统大学 | 靶向癌症治疗的egfr-sglt1相互作用 |
CN104436194A (zh) * | 2013-09-18 | 2015-03-25 | 北京大学 | 具有协同增效作用的抗癌组合物 |
CN110430876A (zh) * | 2017-03-13 | 2019-11-08 | 基恩菲特公司 | 用于组合疗法的药物组合物 |
CN111150848A (zh) * | 2020-01-21 | 2020-05-15 | 中国药科大学 | Plagl2及其在肝癌中的应用 |
Non-Patent Citations (3)
Title |
---|
张伟等: "EGFR与VEGF在食管鳞癌组织中的表达分析" * |
沈莹等: "抗人VEGFR2与抗人EGFR的双特异性重组蛋白治疗结直肠癌的体内外研究" * |
顾晶晶等: "非小细胞肺癌治疗中EGFR与VEGFR-2 的临床意义及相关性分析" * |
Also Published As
Publication number | Publication date |
---|---|
JP7382660B2 (ja) | 2023-11-17 |
EP3957329A4 (en) | 2022-02-23 |
US20220305072A1 (en) | 2022-09-29 |
CN113893350B (zh) | 2023-09-15 |
EP3957329A1 (en) | 2022-02-23 |
CN117018204A (zh) | 2023-11-10 |
JP2022542723A (ja) | 2022-10-07 |
WO2022007135A1 (zh) | 2022-01-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101360422B (zh) | 致癌Ras特异性细胞毒化合物及其使用方法 | |
US9914983B2 (en) | Apoptosis-inducing agent | |
AU2011290818B2 (en) | Combination anti - cancer therapy | |
KR20160051638A (ko) | 암 줄기세포 치료용 조성물 | |
KR20080046161A (ko) | 비-소세포 폐암의 치료를 위한 스타우로스포린 유도체 | |
CN113893350A (zh) | 一种治疗癌症的组合物及其应用和药物 | |
WO2017114260A1 (zh) | 色胺酮及其衍生物在制备hIDO2抑制剂中的用途 | |
JP7381115B2 (ja) | 組成物及びがん治療用医薬品の調製におけるその応用 | |
CN114010789B (zh) | 蟾蜍甾烯类化合物在制备治疗egfr和/或stat3驱动疾病的药物中的应用 | |
CN105283180A (zh) | Pi3k抑制剂与微管去稳定剂的药物组合 | |
CN113230249A (zh) | 土荆皮乙酸在作为或制备Hedgehog信号通路抑制剂中的应用 | |
JP2022542725A (ja) | 化合物又はその薬学的に許容される塩、二量体又は三量体のがん治療用医薬品の調製における応用 | |
KR20130064162A (ko) | 암의 증식, 재발 또는 전이 억제용 의약 조성물 | |
CN103037901A (zh) | 抑制cd36以控制肥胖和胰岛素敏感性 | |
CN106974903A (zh) | 洛铂在制备治疗恶性滋养细胞肿瘤药物中的应用 | |
WO2024056074A1 (zh) | Fak抑制剂及拓扑异构酶抑制剂的药物组合及用途 | |
CN114569727B (zh) | 一种治疗癌症的组合物及其应用和药物 | |
WO2022127788A1 (zh) | 乐伐替尼和Aurora-A激酶抑制剂在制备抑制癌症的药物中的应用 | |
CN116437922A (zh) | 预防转移的靶向γ亚单位的线粒体ATP抑制剂 | |
Zaarour et al. | Role of Hypoxia-Mediated Autophagy in Tumor Cell Death and Survival. Cancers 2021, 13, 533 | |
CN113730582A (zh) | Slc12a5及其抑制剂的应用 | |
CN115919882A (zh) | 刺芒柄花苷在制备预防和/或治疗tdo介导病理特征疾病的药物中的应用 | |
Fan et al. | Expression and significance of nerve growth factor receptor p75 in rats’ cathartic colonic wall | |
CN108771670A (zh) | 一种药物组合物及其在制备抗前列腺癌药物中的应用 | |
WO2013028866A1 (en) | Therapeutic compounds and methods |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40059773 Country of ref document: HK |
|
CB03 | Change of inventor or designer information |
Inventor after: Sun Zhongjie Inventor after: Qi Hailong Inventor after: Liu Defang Inventor after: Yan Xiaoe Inventor after: Li Weiwei Inventor after: Wang Xiaofang Inventor before: Sun Zhongjie Inventor before: Qi Hailong Inventor before: Chen Ligong Inventor before: Xie Huangfan Inventor before: Liu Defang Inventor before: Yan Xiaoe Inventor before: Li Weiwei Inventor before: Wang Xiaofang |
|
CB03 | Change of inventor or designer information | ||
GR01 | Patent grant | ||
GR01 | Patent grant |